Mikhail Kosiborod MD

PubMed

• 1 citations
  Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial.
  Rahul Aggarwal, Deepak L Bhatt, Michael Szarek, Christopher P Cannon, Lawrence A Leiter
  The Lancet. Diabetes & Endocrinology. 2025-04-01
• 1 citations
  Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide.
  Subodh Verma, Francesco Cosentino, Mikhail N Kosiborod
  European Heart Journal. 2025-03-24
• 3 citations
  Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure.
  Mikhail N Kosiborod, David Z I Cherney, Akshay S Desai, Jeffrey M Testani, Subodh Verma
  Journal of the American College of Cardiology. 2025-03-18

Journal Articles

• Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients with Heart Failure with Reduced Ejection Fraction  
  Mikhail N Kosiborod, Marc S Sabatine, JAMA Cardiology
• Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients with Heart Failure with and Without Diabetes  
  Akshay S Desai, Mikhail N Kosiborod, Marc S Sabatine, JAMA
• Real‐World Opportunity of Empagliflozin to Improve Blood Pressure Control in African Americans with Type 2 Diabetes: An NCDR® “Research‐to‐Practice” Project from the D...  
  Suzanne V Arnold, Mikhail Kosiborod, Diabetes, Obesity and Metabolism
• Management of Patients with Diabetes and Heart Failure with Reduced Ejection Fraction: An International Comparison  
  James L Januzzi, Mikhail Kosiborod, Frederick A Masoudi, Darren K McGuire, Suzanne V Arnold, Gregg C Fonarow, Diabetes, Obesity and Metabolism
• Join now to see all

Lectures

• Drug Choices in Diabetes and Heart Failure Advice for the Practicing Cardiologist 
  2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
• Changing Paradigm in Cardiovascular Risk Reduction in Diabetes 
  2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
• Initiation of Sodium Glucose Cotransporter-2 Inhibitors Versus Other Glucose Lowering Drugs and Risk of Hospitalization For Heart Failure and Death in Patients With Ty... 
  2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
• Summary of the ACC Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Diabetes 
  2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
• Comorbid Conditions in Heart Failure: Diabetes and All That Comes With it 
  2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
• Join now to see all